-
Risk Disclosure
- Value Partners Health Care Fund (the “Fund”) primarily invests in equities and equity-related securities in healthcare companies on a worldwide basis.
- The investments of the Fund are concentrated in the health care sector which are subject to greater influences from government policies and regulations than those of other industries. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments.
- Investing in PRC market exposes the Fund to additional risks including currency repatriation risk, uncertainty of taxation policies and risk associated with Stock Connects. The Fund may also expose to RMB currency and conversion risk.
- Investing in small/mid-capitalization securities may have lower liquidity and their prices are more volatile to adverse economic developments.
- The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
- You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.
-
Performance
Performance Update
Annual Returns
Annual Returns
Performance Since Launch as at 24-04-2024
Performance Since Launch
Source: HSBC Securities Services (Ireland) DAC and Bloomberg, in US dollar, NAV to NAV, with dividends reinvested. Performance data is net of all fees. All indices are for reference only.
Please note that investment involves risks. The unit price of the Funds may go down as well as up and past performance of the Fund does not indicate future return. Investors should refer to the Prospectus, Supplement(s) and Key Investor Information Document(s) of the Funds for further details and the risk factors in particular those involved in investing in emerging markets prior to the subscription of the units of the Fund.
Viewers who intend to subscribe for Shares of any Sub-fund of Value Partners Ireland Fund ICAV following publication of the Prospectus, Supplement and Key Investor Information Document are reminded that any such application may only be made on the basis of the information contained in the final Prospectus, Supplement and Key Investor Information Document which may be different from the information contained on this website and which may be subject to updating, amendment and/or completion.
-
Fund Facts
Investment objectives
The Fund aims to achieve long-term capital growth by investing primarily in equities and equity related securities in healthcare companies, such as pharmaceuticals, biotechnology, healthcare services, as well as medical technology and supplies, which derive a significant part of their revenue from the PRC and which are listed on stock markets on a worldwide basis, including mainland China.
Open-ended Umbrella Investment Company Value Partners Ireland Fund ICAV
Promoter and investment manager Value Partners Hong Kong Limited
Depositary HSBC Continental Europe
Legal status Authorized by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities (UCITS) pursuant to the European Communities UCITS Regulations 1
Launch date 02-04-2015Fund size USD78.37 million ( as at 25-04-2024 ) Base currency US dollar
Other currency class available Hedged: AUD, CHF, EUR, GBP, JPY, NZD, RMB, SGD, etc. 2
Unhedged: CHF, EUR, GBP, HKD, USDMinimum subscription Class A: AUD 10,000/ CHF 10,000/ EUR 10,000/ GBP 10,000/ JPY 1,000,000/ SGD 10,000
Class Z: GBP 1,000,000/ USD 1,000,000Initial subscription fee Up to 5% of the issue priceInvestment manager fees Class A: 1.50% per annum
Class Z: 1.00% per annum
Performance fee Nil
Redemption fee Nil
Dealing frequency Daily
Cutoff time: 11.59am Irish time- Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc) is authorized and supervised by the Central Bank of Ireland (“Central Bank”). Authorization by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. Authorization of the ICAV is not an endorsement or guarantee of the ICAV by the Central Bank.
- Transactions for currency hedging purposes may be carried out in respect of shares in the Hedged Classes; for details on this and/or for a full list of share classes, please refer to the prospectus and the relevant fund supplement.
Please note that investment involves risks. The unit price of the Fund(s) may go down as well as up and past performance of the Fund(s) does not indicate future return. Investors should refer to the Prospectus, Supplement(s) and Key Investor Information Document(s) of the Fund(s) for further details and the risk factors in particular those involved in investing in emerging markets prior to the subscription of the units of the Fund(s).
-
Documents
Loading...Type of Document Date Download -
Historical Prices
Loading...
Currently browsing: